PX-12 is primarily investigated for its potential applications in cancer therapy. It functions as an inhibitor of thioredoxin-1 (Trx-1), a protein that plays a crucial role in cancer cell survival and proliferation. By inhibiting Trx-1, PX-12 disrupts the redox balance within cancer cells, leading to increased oxidative stress and ultimately inducing cell death. This mechanism makes it a promising candidate for targeting various types of cancers, particularly those that are resistant to conventional treatments. Additionally, PX-12 has shown potential in reducing tumor growth in preclinical studies, making it a subject of interest for further clinical development. Its ability to enhance the efficacy of other anticancer therapies when used in combination is also being explored.